–Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”)
POMPANO BEACH, FLORIDA, December 19, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
WASHINGTON, DC, December 15, 2023 -As many are aware, Rogue One, Inc. (“Company”) has not submitted any financial statements subsequent to the Quarterly Report dated
New York, December 15, 2023 PRISM MediaWire – Weekly Press Resume Dec. 11 to Dec. 15, 2023 UAT Group Receives Financing for Iron Removal System
– Sales Grew 58% YOY; Backlog Grew 68% YOY and Remains Strong at $10.4 Million; Company Projects 30% Revenue Growth for Fiscal Year ending February
Pricing Provides AmnioWrap2TM Reimbursement in All MAC Regions POMPANO BEACH, FLORIDA, December 14, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company
Installation expected to be Completed in Mid-2024 SAN FRANCISCO, December 13, 2023 – GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE
POMPANO BEACH, FLORIDA, December 13, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived
Dover, DE, December 12, 2023 – Metatron Apps Inc. (OTC: MRNJ), a prominent figure in the digital technology sector with a portfolio boasting over 1000
NEW YORK, NY, December 11, 2023 – The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
